SUMO

PF3D7_0505800 (PfSUMO) is a ~100-amino-acid small ubiquitin-related modifier in Plasmodium falciparum that is covalently conjugated to a broad set of blood-stage parasite proteins spanning the nucleus, parasite cytoplasm, and host-cell Maurer's clefts (PMID:18547337). Among its identified substrates is PfSir2, a telomere-associated nuclear protein, linking PfSUMO conjugation to the parasite's chromatin regulatory machinery (PMID:18547337). Sumoylation of parasite proteins is dynamic across the intraerythrocytic developmental cycle, peaking at mid-stages in concert with hemoglobin consumption and elevated oxidative stress, and PfSUMO conjugation is protective under oxidative challenge (PMID:23943616, PMID:26697886). Conjugation is carried out by parasite-specific E1 and E2 (Pf-Ubc9) enzymes whose E1–E2 binding interface diverges from the human system; surface-accessible aspartate residues on PF3D7_0505800 and N-terminal residues of Pf-Ubc9 dictate the specificity and unidirectional cross-species interactions of the cascade (PMID:23943616, PMID:35331687). PfSUMO-modified proteins can carry heterologous SUMO/ubiquitin mixed conjugates, indicating cross-regulation between the two modifier pathways (PMID:21930698), and conjugates are removed by the SUMO-specific protease PfSENP1, whose cleavage-sequence preference is distinct from human SENPs (PMID:21700207). The pathway is pharmacologically relevant: mutation of the SUMO-activating E1 subunit confers resistance to the benzoxaborole AN13762 (PMID:31992618).

1. 2008 Medium

   Whether P. falciparum possesses a functional SUMO system and where its conjugates act was unknown; demonstrating PfSUMO conjugation across parasite compartments established SUMO as an active post-translational modifier in blood-stage parasites and identified a chromatin-regulatory substrate.

   Evidence Immunofluorescence, Western blot with anti-peptide antibodies, FLAG-tagged overexpression, and two-step IP-LC-MS/MS in P. falciparum

   PMID:18547337

   Open questions at the time

   • Full substrate repertoire beyond PfSir2 not defined
   • Functional consequence of PfSir2 sumoylation on var gene silencing not tested
   • Compartment-specific conjugation dynamics not resolved
2. 2011 High

   It was unclear how PfSUMO conjugates are removed and processed; recombinant characterization of PfSENP1 established a parasite SUMO-specific protease with a cleavage preference distinct from human SENPs, and its inhibitors block parasite replication, nominating deconjugation as a druggable node.

   Evidence Recombinant catalytic-domain expression, positional scanning substrate library profiling, small-molecule inhibitor and parasite growth assays

   PMID:21700207

   Open questions at the time

   • In vivo substrate specificity of PfSENP1 not mapped
   • Whether inhibitor lethality is solely via SUMO deconjugation not established
   • Structure of PfSENP1 not determined
3. 2011 Medium

   Whether PfSUMO cross-talks with ubiquitin was unknown; detection of SUMO/ubiquitin mixed conjugates on parasite proteins established cross-regulation between the two modifier pathways.

   Evidence MudPIT mass spectrometry with complementary immunofluorescence and biochemical assays in P. falciparum

   PMID:21930698

   Open questions at the time

   • Specific dual-modified substrates not identified
   • Functional outcome of mixed conjugates (degradation vs. stabilization) untested
   • Enzymes generating the mixed chains not defined
4. 2013 High

   The timing and enzymatic basis of PfSUMO conjugation were undefined; showing peak sumoylation at mid-cycle under oxidative stress and reconstituting Pf E1/E2 activity established stage-regulated conjugation and revealed a divergent E1–E2 interface that blocks cross-species enzyme pairing.

   Evidence Stage-resolved immunoblotting, in vitro sumoylation reconstitution with recombinant Pf E1/E2 and RanGAP1, structural analysis and mutagenesis

   PMID:23943616

   Open questions at the time

   • Physiological Pf substrates of the reconstituted cascade not confirmed in vitro
   • Causal link between oxidative stress and conjugation peak not mechanistically resolved
   • In vivo requirement of the E1/E2 enzymes not tested by knockout
5. 2015 High

   The residue basis for species-specific SUMO enzyme interactions and the biological role of sumoylation were unclear; structure-guided modeling plus functional assays defined interface residues and demonstrated a protective role for sumoylation during oxidative stress at RBC stages.

   Evidence X-ray crystallography of human E1–E2, in silico modeling, site-directed mutagenesis, in vitro biochemistry, and oxidative-stress treatment of parasites

   PMID:26697886

   Open questions at the time

   • Direct Pf E1–E2 structure not solved (human structure used as guide)
   • Downstream effectors mediating oxidative-stress protection not identified
   • Genetic loss-of-function confirmation of the protective role absent
6. 2020 Medium

   Whether the sumoylation cascade contributes to antimalarial drug action was unknown; identifying E1 (SUMO-activating enzyme subunit 2) mutations that confer AN13762 resistance placed the PF3D7_0505800 pathway in the mechanism of benzoxaborole resistance.

   Evidence In vitro resistance selection, whole-genome sequencing, genome-edited introduction of the mutation, and IC50 determination

   PMID:31992618

   Open questions at the time

   • Whether PfSUMO conjugation itself (vs. E1 enzyme) is the drug target not resolved
   • Molecular mechanism of AN13762 action on the cascade not defined
   • Effect of resistance mutation on baseline sumoylation not reported
7. 2022 Medium

   The molecular determinants of PfSUMO's interaction with E2 were incompletely defined; biophysical dissection showed a unidirectional cross-species interaction driven by surface aspartates on PF3D7_0505800 and N-terminal residues of Pf-Ubc9.

   Evidence Biochemical binding and biophysical interaction assays with site-directed mutagenesis of Pf-SUMO surface residues and Pf-Ubc9 N-terminus

   PMID:35331687

   Open questions at the time

   • Consequences of interface residues for in vivo conjugation efficiency untested
   • Co-structure of the Pf-SUMO–Pf-Ubc9 complex not determined
   • Whether these residues are exploitable for selective inhibitors unexplored

• The genome-wide PfSUMO substrate landscape and the phenotypic consequences of blocking PfSUMO conjugation in vivo remain undefined.
• No conditional knockout/knockdown of PF3D7_0505800 reported
• Comprehensive substrate proteome beyond PfSir2 not mapped
• Direct 3D structure of PfSUMO (beyond NMR resonance assignments) not solved